ELQ-300|cas:1354745-52-0|西域试剂

ELQ-300,98.0%

产品编号：Bellancom-13836| CAS NO：1354745-52-0| 分子式：C₂₄H₁₇ClF₃NO₄| 分子量：475.84

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-13836	￥1500.00	杭州北京（现货）
Bellancom-13836	￥2400.00	杭州北京（现货）
Bellancom-13836	￥4800.00	杭州北京（现货）
Bellancom-13836	￥7700.00	杭州北京（现货）
Bellancom-13836	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ELQ-300

产品介绍

ELQ-300 是一种有效的、有口服生物活性的抗疟疾剂，结合并抑制细胞色素 bc₁ 复合物 (cyt bc₁) 的还原 (Q_i) 位点。ELQ-300 抑制恶性疟原虫 Dd2，Tm90-C2B 和 D1 的 IC₅₀ 值分别为 6.6，4.6 和 160 nM。ELQ-300 可用于抗疟疾的研究。

生物活性

ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Q_i) site of the cytochrome bc₁ complex (cyt bc₁). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC₅₀ values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial.

体外研究

ELQ-300 (0-70 nM, 21 d) inhibits P. falciparum Dd2, Tm90-C2B, and D1 growth with IC₅₀ values of 6.6, 4.6 and 160 nM, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ELQ-300 (1 and 10 mg/kg; p.o. once daily for 1 or 4 days) inhibits P. yoelii growth in an acute infection model.
ELQ-300 (10 and 20 mg/kg; p.o. once daily for 1 or 4 days) prevents recurrence of infection in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week female CF-1 mice with P. yoelii-WT infection
Dosage:	1 and 10 mg/kg
Administration:	Oral gavage; 1 mg/kg once daily for 4-day; 10 mg/kg once daily for 1-day
Result:	Inhibited P. yoelii with ED₅₀ values of 0.04 and 0.03 mg/kg for 4-day dosing and 1-day dosing, respectively.

Animal Model:	6-week female CF-1 mice with P. yoelii-WT infection
Dosage:	10 and 20 mg/kg
Administration:	Oral gavage; 10 mg/kg once daily for 4-day; 20 mg/kg once daily for 1-day
Result:	Effectively prevented recrudescence in the 4-day dosing studies with infection mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week female CF-1 mice with P. yoelii-WT infection
Dosage:	1 and 10 mg/kg
Administration:	Oral gavage; 1 mg/kg once daily for 4-day; 10 mg/kg once daily for 1-day
Result:	Inhibited P. yoelii with ED₅₀ values of 0.04 and 0.03 mg/kg for 4-day dosing and 1-day dosing, respectively.

Animal Model:	6-week female CF-1 mice with P. yoelii-WT infection
Dosage:	10 and 20 mg/kg
Administration:	Oral gavage; 10 mg/kg once daily for 4-day; 20 mg/kg once daily for 1-day
Result:	Effectively prevented recrudescence in the 4-day dosing studies with infection mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 15.62 mg/mL (32.83 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1015 mL	10.5077 mL	21.0155 mL
5 mM	0.4203 mL	2.1015 mL	4.2031 mL
10 mM	0.2102 mL	1.0508 mL	2.1015 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.25 mg/mL (4.73 mM); Suspended solution; Need ultrasonic

此方案可获得 2.25 mg/mL (4.73 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液